journal
MENU ▼
Read by QxMD icon Read
search

Pharmaceutical Patent Analyst

journal
https://read.qxmd.com/read/30657422/ensifentrine-rpl554-an-inhaled-bifunctional-dual-pde3-4-inhibitor-for-the-treatment-of-asthma-and-chronic-obstructive-pulmonary-disease
#1
Mario Cazzola, Clive Page, Luigino Calzetta, Maria Gabriella Matera
Ensifentrine (RPL554), an inhaled 'bifunctional' dual phosphodiesterase 3/4 inhibitor that exhibits both bronchodilator and anti-inflammatory activities, provides a new option in the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases that are under clinical development. Ensifentrine appears to be initially under development for the treatment of COPD although it is not yet clear whether it should be understood as an add-on therapy in patients for the treatment of acute exacerbations of COPD or for the regular maintenance treatment of patients either alone, or on top of existing drug classes...
January 18, 2019: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/30657414/therapeutic-use-of-fluorinated-nucleosides-progress-in-patents
#2
Marcella Bassetto, Magdalena Slusarczyk
Fluorinated nucleosides constitute a large class of chemotherapeutics approved for clinical use. The pharmacokinetic and pharmacodynamic properties of a drug can be affected, as a consequence of modulation of electronic, lipophilic and steric parameters, by the introduction of fluorine into the structure of drug-like molecule. Herein, we focus on fluorinated-nucleoside analogs, their therapeutic use and applications based on the patent literature from 2014 to 2018. We briefly discuss the clinical properties of anticancer and antiviral fluorine-containing nucleos(t)ides US FDA-approved or in development, and highlight their resistance mechanisms and limitations in the clinic...
January 18, 2019: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/30657413/discussions-on-the-new-molecular-formula-and-new-molecular-entity-definitions-of-pharmaceutical-innovation
#3
Mehul Gupta, Sunand Kannappan
No abstract text is available yet for this article.
January 18, 2019: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/30632452/reaching-a-milestone-in-pharmaceutical-patenting-in-brazil
#4
Gabriel Di Blasi
No abstract text is available yet for this article.
January 11, 2019: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/30632451/patent-highlights-june-july-2018
#5
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
January 11, 2019: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/30632447/selective-and-nonselective-hdac8-inhibitors-a-therapeutic-patent-review
#6
Nilanjan Adhikari, Sk Abdul Amin, Tarun Jha
Histone deacetylase 8 (HDAC8) is one of the attractive therapeutic anticancer targets. HDAC8 has been overexpressed in a variety of human cancers. Therefore, HDAC8 inhibitors offer beneficial effects in the treatment of solid and hematological tumors. Different HDAC inhibitors entered into different phases of clinical studies. However, selectivity towards specific HDAC8 enzyme is still demanding. In this patent review, a number of patented selective and nonselective HDAC8 inhibitors along with their implication as anticancer agents have been discussed in details...
January 11, 2019: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/30101657/what-is-holding-up-the-unified-patent-court
#7
Liz Cohen, Alan Johnson
A form of unified patent protection has been available in Europe since the 1970s, but enforcement remains purely a national matter. After many years' negotiation, an agreement was signed in February 2013 to create a pan-European court (the UPC), potentially affecting global litigation strategies. A constitutional complaint brought in Germany in 2017 has delayed the project and potentially presents an existential challenge, but more likely the issue is how much further delay it will cause. It remains entirely possible the UPC will start in Q1 2019 (before Brexit)...
September 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/30066608/three-years-on-from-teva-where-are-we-now
#8
Kenneth R Adamo, Eugene Goryunov, Ryan M Hubbard, Sarah M Craig
No abstract text is available yet for this article.
September 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/30066605/gallium-68-methodology-and-novel-radiotracers-for-positron-emission-tomography-2012-2017
#9
Sean S Tanzey, Stephen Thompson, Peter Jh Scott, Allen F Brooks
Commercial 68 Ge/68 Ga generators provide a means to produce positron emission tomography agents on site without use of a cyclotron. This development has led to a rapid growth of academic literature and patents ongallium-68 (68 Ga). As 68 Ga positron emission tomography agents usually involve a targeting moiety attached to a metal chelator, the development lends itself to the investigation of theragnostic applications; the 68 Ga-based diagnostic is utilized to determine if the biological target is present and, if so, a therapeutic isotope (e...
September 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/30066594/advances-in-patented-cb1-receptor-antagonists-for-obesity
#10
EDITORIAL
Mange Ram Yadav, Prashant R Murumkar
No abstract text is available yet for this article.
September 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/29882730/novel-patented-markers-of-immune-checkpoint-inhibitor-efficacy
#11
EDITORIAL
Matthieu Collin
No abstract text is available yet for this article.
July 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/29882729/patent-highlights-february-march-2018
#12
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research development.
July 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/29882724/celastrol-as-a-pentacyclic-triterpenoid-with-chemopreventive-properties
#13
REVIEW
Priya Yadav, Vishal Jaswal, Ajay Sharma, Dharambir Kashyap, Hardeep S Tuli, Vivek K Garg, Shonkor K Das, R Srinivas
Celastrol is a highly investigated anticancer moiety. It is a pentacyclic triterpenoid, isolated several decades ago with promising role in chemoprevention. Celastrol has been found to target multiple proinflammatory, angiogenic and metastatic proteins. Inhibition of these targets results in significant reduction of cancer growth, survival and metastasis. This review summarizes the varied molecular targets of celastrol along with insight into the various recently published clinical, preclinical and industrial patents (2011-2017)...
July 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/29882720/spc-update-advocate-general-opines-on-the-meaning-of-protected-by
#14
EDITORIAL
Saufung Ma, Belinda Lavin
No abstract text is available yet for this article.
July 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/29882718/disruption-and-development-the-evolving-crispr-patent-and-technology-landscape
#15
Daniel Lim
No abstract text is available yet for this article.
July 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/29882713/arrow-declarations-here-to-stay-or-a-flash-in-the-pan
#16
Dominic Adair
No abstract text is available yet for this article.
July 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/29676653/tissue-targeted-nanocapsids-for-oral-insulin-delivery-via-drink
#17
Chun C Chen, Mo A Baikoghli, R Holland Cheng
For the past eight decades, subcutaneous injection has been the main route used for supplementing the suboptimal insulin secretion for administering insulin as a treatment for diabetes mellitus. Although this method is effective, subcutaneous injections are painful, inconvenient and carry a high risk of infections leading to poor patient compliance. The insulin-encapsulated hepatitis E virus nanoparticle, composed of the noninfectious hepatitis E viral capsid, is expected to deliver insulin from the GI tract to the liver after ingestion...
May 1, 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/29676211/patent-highlights-from-december-2017-to-january-2018
#18
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
May 1, 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/29629839/advances-in-patented-interpenetrating-polymeric-networks-for-biomedical-applications
#19
Pradeep Kumar, Yahya E Choonara, Lisa C du Toit, Viness Pillay
No abstract text is available yet for this article.
May 1, 2018: Pharmaceutical Patent Analyst
https://read.qxmd.com/read/29629820/recent-gene-delivery-patents-for-treatment-of-atherosclerosis
#20
Ambikanandan Misra
No abstract text is available yet for this article.
May 1, 2018: Pharmaceutical Patent Analyst
journal
journal
47821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"